Loading clinical trials...
Loading clinical trials...
EXTEND (Eltrombopag Extended Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study.
Conditions
Interventions
eltrombopag olamine (SB-497115-GR)
Locations
110
United States
Novartis Investigative Site
Huntsville, Alabama, United States
Novartis Investigative Site
Mobile, Alabama, United States
Novartis Investigative Site
Jonesboro, Arkansas, United States
Novartis Investigative Site
Duarte, California, United States
Novartis Investigative Site
Los Angeles, California, United States
Novartis Investigative Site
San Francisco, California, United States
Start Date
June 1, 2006
Primary Completion Date
July 1, 2015
Completion Date
July 1, 2015
Last Updated
April 17, 2017
NCT00908037
NCT01072162
NCT00442871
NCT01064336
NCT01098487
NCT00424177
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions